Original Contribution |
From the Department of Pathology and Laboratory Medicine, University of Cincinnati Medical Center, Ohio.
Correspondence to Muhammad Ashraf, PhD, Department of Pathology and Laboratory Medicine, University of Cincinnati Medical Center, 231 Bethesda Ave, Cincinnati, OH 45267-0529.
| Abstract |
|---|
|
|
|---|
was
translocated to the mitochondria, intercalated disks, and nuclei of
myocytes in diazoxide-pretreated hearts, and PKC-
and PKC-
were
translocated to sarcolemma and intercalated disks, respectively. This
study suggests that the effect of the MitoKATP channel is
mediated by PKC-mediated signaling pathway.
Key Words: K+ channel Ca2+ paradox Ca2+ preconditioning protein kinase C diazoxide
| Introduction |
|---|
|
|
|---|
To understand these mechanisms, we plan to use the reverse strategy of testing interventions to discover cellular pathways that lead to reduction of Ca2+ PD injury. A mild stress induced by brief Ca2+ depletion and repletion, called Ca2+ preconditioning,2 has been shown to protect the myocardium from Ca2+ PD injury or subsequent sustained ischemia/reperfusion.7 Protein kinase C (PKC) was shown to be a major component in the attenuation of cell injury caused by Ca2+ preconditioning (CPC). Recent evidence suggests that the MitoKATP channel is mainly involved in preconditioning against ischemia/reperfusion.8 9 Garlid and his colleagues 10 reported that the KATP channel from cardiac mitochondria is 2000 times more sensitive to diazoxide than the sarcolemmal channel, which indicates that 2 distinct channel subtypes coexist within the myocyte. Liu and colleagues 9 also reported that diazoxide targets mitochondrial but not sarcolemmal KATP channels. We have previously shown that CPC elicits its protection through PKCmediated signaling pathways.7 Therefore, it appears that the effects of both PKC and the MitoKATP channel are interlinked. Accordingly, we hypothesize that diazoxide opens both MitoKATP channels and activates PKC. The results of this study show that the participation of PKC is essential in MitoKATP channelmediated cardiac protection.
| Materials and Methods |
|---|
|
|
|---|
, 651 to 672; ßI, 656 to 671;
ßII, 657 to 673;
, 679 to 697;
, 657 to
673;
, 722 to 736;
, 669 to 683; and
, 573 to 592).
Indocarbocyanine-conjugated anti-rabbit IgG antibody was purchased from
Jackson ImmunoResearch Laboratories, Inc. PMA and diazoxide were
dissolved in DMSO before being added into the perfusion buffer. The
final concentration of DMSO was <0.1%. Other reagents were dissolved
in PBS. All the agents except diazoxide and PMA were directly
administered through the aortic cannula at a rate of 0.2 mL/min by use
of a Harvard infusion pump.
Heart Preparation
The current study conforms with the Guide for the Care and
Use of Laboratory Animals published by the US National Institutes
of Health (NIH, Publication No. 8523, revised 1985). Male
Sprague-Dawley rats that weighed 250 to 300 g were
anesthetized by an intraperitoneal
injection of 30 mg/kg pentobarbital. After
intraperitoneal injection of 500 U/kg heparin
sodium, hearts were removed and retrogradely perfused through the aorta
in a noncirculating Langendorff apparatus with
Krebs-Henseleit (KH) buffer, which consisted of the following (mmol/L):
NaCl 118, KCl 4.7, MgSO4 1.2,
KH2PO4 1.2,
CaCl2 1.8, NaHCO3 25, and
glucose 11. The buffer was saturated with 95%
O2/5% CO2 (pH 7.4, 37°C)
for 50 minutes. Hearts were perfused at a constant pressure of 80
mm Hg. A water-filled latex balloontipped catheter was inserted into
the left ventricle through the left atrium and was adjusted to a left
ventricular end-diastolic pressure (LVEDP) of 4
to 6 mm Hg during the initial equilibration. Thereafter, the
balloon volume was not changed. The distal end of the catheter was
connected to a heart performance analyzer (Digi-Med
model 210, version 1.01, Micro-Med) via a pressure transducer. Hearts
were paced at 350 bpm except during periods of
Ca2+ depletion in all groups. The index of
myocardial function was determined with left ventricular
developed pressure, which was calculated from the difference between
left ventricular peak systolic pressure and
end-diastolic pressure. Left ventricular
systolic pressure, end-diastolic pressure, and the
derivative of left ventricular pressure (±dP/dt) were
recorded continuously as a function of time by personal computer
(International Computer Technology, Inc). After perfusion with the
oxygenated KH buffer for an equilibration period of 25
minutes, a 3-way stopcock above the aortic root was used to perfuse the
Ca2+-free KH buffer for 10 minutes, followed by a
KH buffer that contained Ca2+ for 10 minutes, to
induce a typical Ca2+ PD.2 The
coronary effluent was collected in a beaker, and the
coronary flow was determined volumetrically at the
pretreatment; just before being subjected to Ca2+
depletion; during the Ca2+ depletion period; and
at 1, 3, 5, and 10 minutes during Ca2+
repletion.
Experimental Protocol
After equilibration, hearts were randomly divided into
experimental groups.
Group 1: Normal Control and Vehicle Control
Hearts (n=6) were perfused for 45 minutes with KH buffer as a
normal control for different experimental groups. Rat hearts were
pretreated for 6 minutes with vehicle (0.01% DMSO, n=6) followed by a
5-minute washout, after which the hearts were subjected to the
Ca2+ PD. The amounts of DMSO used in vehicle
control experiments did not affect any hemodynamic
parameters, lactate dehydrogenase (LDH) release, ATP
content, or cell morphology (data not shown).
Group 2: Ca2+ PD
After a 25-minute perfusion with normal KH buffer, hearts (n=8)
were subjected to Ca2+-free KH buffer for 10
minutes followed by KH buffer that contained Ca2+ for 10
minutes.
Group 3A: Ca2+ Preconditioning and Calcium Paradox
This group was designed to determine whether CPC elicits
protection against Ca2+ PD. Hearts (n=8) were
perfused for 3 cycles of 1 minute each with
Ca2+-free KH buffer followed by 5 minutes with
Ca2+-containing KH buffer; then, the hearts were
subjected to Ca2+ PD as in group 2.
Group 3B: 5-HD, CPC, and Ca2+ PD
The rationale for this experiment was that CPC
activates MitoKATP channels, which
results in attenuation of cellular injury. To test this, 5-HD, a
specific blocker of MitoKATP channels, was used
during CPC.
Hearts (n=8) were perfused in a manner similar to that used for group 3A, except that 5-HD (100 µmol/L) was infused for 4 minutes before CPC. The dose of 5-HD was chosen on the basis of a previous report.8
Group 3C: Chelerythrine Chloride, CPC, and Ca2+ PD
This group tested whether the inhibition of PKC during CPC also
abrogates the protection. Chelerythrine chloride was added instead of
5-HD. Hearts (n=8) were perfused in a manner similar to that used in
group 3A, except that chelerythrine chloride (6.4 µmol/L), a
specific PKC inhibitor, was infused through the aorta at a
rate of 0.2 mL/min for 4 minutes before CPC. The dose of chelerythrine
chloride was chosen on the basis of a previous
report.7
Group 4: Role of MitoKATP Channels in Cardiac
Protection
Diazoxide, a potent opener of the MitoKATP
channel, was used during Ca2+ PD. Diazoxide opens
the sarcolemmal KATP channel at a higher
concentration (855 µmol/L=K 1/2), whereas it opens the
MitoKATP channel at a low concentration (0.4
µmol/L=K 1/2).10 This group will determine
whether this specific opener of MitoKATP channels
mimics the effect of CPC. An inhibitor of mitochondrial
KATP channels 5-HD was used to determine whether
MitoKATP channels play an important role in the
prevention of cell injury. It has been reported that 5-HD abolishes the
protective effects of KATP channel openers,
although it has no effect on the ADP-shortening activity, which
suggests its high specificity for MitoKATP
channels.11
Group 4A: Diazoxide and Ca2+ PD
Hearts were perfused with KH buffer that contained diazoxide for
6 minutes and then washed out for 5 minutes. After the hearts
were washed, they were subjected to the Ca2+ PD.
A dose response of diazoxide with 1, 30, 40, 80, and 100 µmol/L
was studied (n=6 to 10 hearts for each subgroup). We found 80
µmol/L diazoxide to have the optimal effect on the
Ca2+ PD injury.
Group 4B: 5-HD, Diazoxide, and Ca2+ PD
Hearts (n=8) were perfused similarly to group 4A except 5-HD
(100 µmol/L) was infused before the use of diazoxide.
Group 5: Influence of PKC on MitoKATP Channel
To determine whether the direct activation of PKC protects the
myocardium independent of MitoKATP
channels, we used the PKC activator PMA.
Group 5A: PMA and Ca2+ PD
Hearts (n=8) were perfused with KH buffer that contained PMA
(100 nmol/L) for 6 minutes followed by a 5-minute washout before the
Ca2+ PD. The dose of PMA was chosen on the basis
of a previous report.11
Group 5B: Chelerythrine Chloride, Diazoxide, and
Ca2+ PD
To determine whether diazoxide activates
MitoKATP channels via a PKC signaling pathway,
hearts (n=8) were perfused by a method similar to group 4A except
chelerythrine chloride (6.4 µmol/L) was infused through the
aorta at the rate of 0.2 mL/min for 4 minutes before diazoxide was
added.
Group 6: Verapamil or Nifedipine,
Diazoxide, and Ca2+ PD
These experiments tested the hypothesis that diazoxide is linked
to transient Ca2+ increase, which was responsible
for the cardioprotection available through the PKC signaling pathway.
The Ca2+ entry was blocked by
verapamil or nifedipine, which are both L-type
Ca2+ channel blockers.
This group was similar to group 4A except that verapamil (2 µmol/L) or nifedipine (0.001 µmol/L) was infused at a rate of 0.2 mL/min for 4 minutes before diazoxide administration (n=6 to 8). After a 5-minute washout, Ca2+ PD was instituted. The doses of verapamil and nifedipine were chosen on the basis of a previous report.12 13
| Measurement of LDH |
|---|
|
|
|---|
| Measurement of Tissue ATP |
|---|
|
|
|---|
| Immunofluorescence Microscopy |
|---|
|
|
|---|
,
PKC-ßI, PKC-ßII,
PKC-
, PKC-
, PKC-
, PKC-
, and PKC-
) were diluted with PBS
that contained 0.1% BSA. Sections were incubated for 1 hour at room
temperature with diluted primary antibodies and then washed with PBS 3
times (3 minutes each). Sections were then incubated for 45 minutes
with indocarbocyanine-conjugated goat anti-rabbit IgG, then washed once
with 0.1% Triton X-100 in PBS for 3 minutes, and washed twice with PBS
(2 minutes each). Nuclear staining was achieved with bis-benzamide (10
mg/mL in PBS) for 30 seconds and washed with PBS 3 times (2 minutes
each). Sections were mounted with a medium (Antifade, Oncor) and were
examined and photographed with a microscope equipped with
fluorescence optics (BH-2 with a PM-CBSP camera, Olympus).
Confocal images were also obtained with a Leitz DME
fluorescence microscope with a TCS 4D confocal scanning
attachment (Leica, Inc). Fluorescence was excited by the 568-nm
line of krypton laser, and the emission was recorded at 568 to 580
nm. | Morphological Examination |
|---|
|
|
|---|
| Statistical Analysis |
|---|
|
|
|---|
| Results |
|---|
|
|
|---|
|
|
|
|
|
Effects of MitoKATP Channel and PKC and
Ca2+ Preconditioning on Ca2+ PD
Intracellular ATP was preserved in diazoxide-treated hearts
(Figure 2
). However, no significant differences existed in LDH
release and tissue ATP levels between diazoxide- and CPC-treated hearts
after Ca2+ repletion. After
Ca2+ repletion, most of the hearts pretreated
with PMA, CPC, or diazoxide exhibited a weak beat. In diazoxide- or
CPC-treated hearts, maximum LDH release was reduced significantly
(P<0.05) compared with Ca2+ PD hearts
(Figure 1
).
At the end of Ca2+ repletion, a significant
improvement in coronary flow and LVEDP was observed in
diazoxide-treated, PMA-treated, and CPC hearts versus hearts subjected
to Ca2+ PD alone. The cellular structure was also
markedly preserved in the diazoxide-treated and CPC hearts. In
diazoxide-pretreated hearts, 49.3% of cells were normal and 17.4% and
33.3% were mildly and severely damaged, respectively (Table 2
).
After a 10-minute period of Ca2+-free perfusion,
tissue showed considerable separation of cells at the intercalated
disks. This separation of the intercalated disks in
diazoxide-pretreated hearts was at a lower scale (Figure 3K
)
than that in control Ca2+ PD hearts.
In a separate series of experiments, we determined the effect of the
5-HD on the cardiac protection elicited by CPC. The hearts treated with
5-HD during CPC stopped beating. In chelerythrine-treated hearts during
CPC, LVEDP and LDH release were significantly increased and CF and
tissue ATP levels were similar to those of the
Ca2+ PD group (Table 1
, Figures 1
and 2
). Similarly, during CPC, 5-HDtreated hearts underwent
drastic morphological changes (Table 2
, Figure 3
).
Similarly, the blockade of MitoKATP channels with
5-HD during diazoxide treatment caused a loss of contractile function
during Ca2+ repletion.
Effect of Diazoxide on PKC Activation
To determine whether MitoKATP channel
opening by diazoxide is mediated via PKC signaling pathways, hearts
were pretreated with chelerythrine. The contractile function in hearts
treated with chelerythrine and diazoxide was lost. LVEDP, maximum LDH
release, coronary flow, and tissue ATP levels were similar to
the Ca2+ PD group (Table 1
, Figures 1
and 2
). Morphological damage was also significantly
higher in hearts pretreated with chelerythrine (Table 2
, Figure 3
).
Diazoxide and Blockade of L-Type Ca2+ Channel
To determine whether a transient increase in
[Ca2+]i during diazoxide
infusion triggers cardioprotection, we attempted to reduce
Ca2+ entry during diazoxide treatment. The
protective effect of diazoxide was abolished in hearts pretreated with
verapamil or nifedipine (Table 1
).
Maximum LDH release was significantly higher, and loss of tissue ATP
content was similar to nontreated hearts (Figures 1
and 2
). In separate experiments, the hearts treated with only
verapamil or nifedipine did not exhibit any
beneficial effects (data not shown).
Immunocytochemical Distribution of PKC Isoforms After Various
Interventions
Representative results from the
immunohistochemical study are shown in Figure 4
. PKC-
, which was diffusely
distributed in the cytoplasm of cells in control, was distinctly
localized in the cardiac cell sarcolemma. PKC-
was positively
localized in the mitochondrial sites, intercalated disks, and nuclei of
myocytes in diazoxide-treated hearts. PKC-
was localized in the
intercalated disks of >90% of cells in diazoxide-pretreated hearts.
PKC-ßI staining was observed in the nuclear
region. PKC-
, PKC-
, PKC-
, and PKC-ßI
showed diffuse nonspecific immunofluorescence in
heart treated with 5-HD, chelerythrine, or verapamil during
diazoxide-pretreatment, respectively. (Only PKC-
isoforms were shown
in hearts treated with 5-HD, chelerythrine, or verapamil,
respectively, during diazoxide-pretreatment.) Staining with
PKC-ßII, PKC-
, PKC-
, and PKC-
was less
intense and weaker than with PKC-
, -
, -
and
-ßI isoforms after diazoxide treatment.
|
| Discussion |
|---|
|
|
|---|
to the cell membrane and PKC-
to the mitochondrial sites was
dominant, although PKC-ßI and PKC-
were
distributed in the nuclear region and intercalated disks, respectively,
in diazoxide-pretreated hearts.
Role of the Diazoxide on Cardioprotection
The activation of the sarcolemmal KATP
channel shortens the action potential duration subsequent to increased
K+ efflux and decreased
Ca2+ influx via voltage-gated channels, which
leads to attenuation of cellular damage during
ischemia.16 However, several studies from other
laboratories showed a poor correlation between sarcolemmal
K+ currents and cardioprotection by ATP-sensitive
K+ channel openers (KCOs).8
Recognition of the MitoKATP channel as an
intracellular receptor for KCOs adds a new dimension to the KCO
pharmacology.10 Recently, the
MitoKATP channel has been proposed as the site of
cardioprotective action.17 Diazoxide is reported to be a
specific opener of MitoKATP
channels.18 19 Although the
physiological functions of
MitoKATP channel are unclear,
Szewczyk20 pointed out that the opening of the
MitoKATP channel partially compensates the
membrane potential, which enables additional protons to be pumped out
to form a H+ electrochemical gradient for both
ATP synthesis and Ca2+ transport. Mitochondria
are known to play at least 2 roles that are essential for cell
survival: ATP synthesis and maintenance of
Ca2+ homeostasis. During aerobic
physiological conditions, a micromolar increase in
Ca2+ concentration stimulates the Krebs cycle and
NADH redox potential, which is essential for ATP synthesis. High-energy
production is essential to support the action of ATP-dependent
ion pumps, such as Na+/K+
and Ca2+ pumps,21 to maintain
membrane intactness and calcium ion gradients across various cell
membranes, including the sarcolemma, sarcoplasmic reticulum, and
mitochondria.22 Xu and colleagues.23 proposed
that glycolytically derived ATP is functionally coupled to
Ca2+ transport by cardiac sarcoplasmic reticulum.
Combined, it is possible that the enhancement of ATP production
in the preconditioned heart by diazoxide maintains the
Ca2+ homeostasis. The action of the
electrophoretic K+ uniport and the electroneutral
K+/H+ exchange by opening
the MitoKATP channel is believed to be primarily
responsible for the maintenance of potassium homeostasis within
the mitochondrion and the control of intramitochondrial osmotic
pressure and mitochondrial volume, which are important in the
modulation of metabolic processes.24
Janczcwski and colleagues25 and Wendt-Gallitelli and
Isenberg26 reported that Ca2+
transient in the mitochondrial matrix is important for ATP synthesis. A
Ca2+ increase within the
physiological range stimulates the activity of 3
enzymes: pyruvate dehydrogenase, isocitrate dehydrogenase, and
-ketoglutarate dehydrogenase. Ca2+-induced
increases in NADH redox potential might increase the rate of ATP
synthesis.27 28 Ca2+ transient
increase also activates Ca2+-dependent
PKC isoforms, which leads to cardioprotection. In addition,
mitochondria may participate directly in Ca2+
homeostasis by means of separate influx and efflux pathways located
within the inner mitochondrial membrane,27 29 which may
also regulate mitochondrial volume by opening
MitoKATP channels. The total mitochondrial
capacity for Ca2+ accumulation is at least
several times larger than that of the sarcoplasmic
reticulum,30 which suggests a key mitochondrial role for
the maintenance of Ca2+ homeostasis
during pathological conditions when cytosolic
Ca2+ concentration increases substantially. An
interesting finding of our study was that verapamil
and nifedipine abolished the protective effect of
diazoxide. This finding was consistent with our previous report
that the protective effect of calcium preconditioning was abolished
with verapamil.12 It is possible that
diazoxide-induced cardiac protection is also shared by
[Ca2+]i-triggered
pathways. Diazoxide may also open sarcolemmal channels in smooth
muscle.31 However, it may seem to be selective in the
heart and liver mitochondria. Also, diazoxide is a potent
vasodilator31 and has little effect on the duration of
cardiac action potential.9 32 The opening of
MitoKATP channels by diazoxide may be a necessary
component for higher ATP production to support an increased
workload in the heart.10 Thus, a major goal in this study
was to preserve as much membrane function and energy production
as possible to delay calcium overload and cell damage. Therefore, in
light of these functions, it is reasonable to propose that the opening
of MitoKATP channels by diazoxide elicits a
unique cardiac protection by delaying Ca2+
overload injury.
Role of PKC on the Activation of the MitoKATP Channel
by Diazoxide and Its Cardioprotection
PKC is a key enzyme in the regulation of signal transduction and
cell growth and differentiation in many cell types.33 34
The role of PKC in preconditioning has been well established by several
investigations.35 36 The current study demonstrates that
Ca2+ plays an important role in the activation of
various second messenger pathways including PKC. This is supported by
the current data that the blockade of Ca2+
increase by verapamil inhibits PKC activation and its
effect on MitoKATP channels. Thus, it is clear
that Ca2+ influx from the exterior of cells is
required for PKC and MitoKATP channel activation.
The latter observation can only be substantiated by direct measurement
of [Ca2+]i transient.
However, the participation of Ca2+ in the
diazoxide-induced protection may have some relevance because diazoxide
is also a known inhibitor of
phosphodiesterase,37 38 and this enzyme degrades
cAMP.39 Therefore, an increase in cAMP influences cellular
functions. It has been reported that inhibition of phosphodiesterase
causes an increase in cAMP in myocytes, which, in turn,
activates protein kinases that modulate L-type
Ca2+ channels such that additional channels open
during each depolarization, which leads to an elevated
Ca2+ transient.40
The role of Ca2+ in mediating protection against
lethal ischemia and Ca2+ overload via PKC
has been established by our previous studies2 12 15 41 and
by others as well.42 43 Administration of PKC
activator PMA produces cardioprotection against
Ca2+PD similar to that by diazoxide. This finding
was also supported by Sato and colleagues11 who pointed
out that the activity of the MitoKATP channel
could be regulated by PKC in intact heart cells. Exposure to PMA
potentiated and accelerated the effect of diazoxide. The effects of PMA
were blocked by the MitoKATP channel blocker
5-HD, which was verified with simultaneous
recordings of membrane current and flavoprotein
fluorescence. In the latter studies, DeWeille and
colleagues44 also demonstrated that stimulation of PKC by
the phorbol ester PMA activated the KATP
channel. Therefore, the PKC-mediated pathway appears to be important in
preconditioning of the isolated rat heart. Because the
KATP channel from cardiac mitochondria is
2000
times more sensitive to diazoxide than the channel from cardiac
sarcolemma,10 it is reasonable to speculate that PKC
activation might phosphorylate both the sarcolemmal
KATP and MitoKATP
channels.
Diazoxide perhaps stimulates both PKC and MitoKATP channels, thus conferring a greater protection as suggested by increased ATP preservation and better cardiac function. The inhibition of MitoKATP channel-mediated effects by chelerythrine further reinforced the notion that PKC regulates intracellular processes not only by direct phosphorylation of numerous rate-limiting enzyme targets but also by initiating other protein kinase cascades.45 46 Although diazoxide activation of PKC appears to be Ca2+ dependent, there may be cross talk between different second messenger systems, both Ca2+-dependent and -independent, which may act synergistically to induce protection. Given the strategic importance of mitochondria in the cardiac cell, the mitochondrial site of action deserves further molecular characterization.
Translocation of PKC activity from cytosolic to particulate
compartments is commonly used as an index of PKC
activation.47 We used immunohistochemistry to determine
subcellular localization of PKC isoforms. Although this technique
primarily provides only qualitative data, the use of isoform-specific
anti-PKC antibodies allows the assessment of both isoform-selective
activation and compartmentation.48 We confirmed the
movement of PKC-
, PKC-
, PKC-
, and
PKC-ßI in diazoxide-pretreated hearts. These
results are consistent with our previous report that a
transient rise in Ca2+ as a result of
Ca2+ preconditioning mediated the translocation
of PKC-
to the cell membrane.12 An interesting finding
of this study is that PKC-
was predominantly translocated to the
mitochondrial sites after diazoxide treatment. Because PKC-
,
PKC-
, and PKC-ßI are Ca2+-insensitive
isoforms, it appears that diazoxide affects both
Ca2+-dependent and -independent pathways. The
question whether diazoxide increases the
[Ca2+]i transient remains
unanswered in this study because we did not directly measure
intracellular [Ca2+]i
during the pretreatment period. However, the diazoxide effect was
blocked by verapamil and nifedipine, which
suggests Ca2+ influx through these channels by
diazoxide treatment. Because no reduction in cellular injury was
observed in the hearts subjected to the Ca2+ PD,
it is unlikely that myocardium injury is reduced with the
concentration of the Ca2+ channel blockers used
in this study. The activation of Ca2+-dependent
PKC-
strongly suggests a rise in
[Ca2+]i, which was
attributed to Ca2+ influx from the extracellular
space. Ca2+ could also be released from preloaded
mitochondria by opening of MitoKATP
channels.49 The translocation of PKC-
isoform is also
consistent with our previous studies with CPC in which a modest
increase in [Ca2+]i
played an important role in PKC-mediated pathways.12
PKC-
does not require Ca2+ for activation but
requires diacylglycerol (DAG) and
phosphatidylserine, a component of the plasma
membrane.32 48 Transient increase in
[Ca2+]i as stated above
activates Ca2+-dependent isoforms of PKC
and phospholipase Creleasing 1,4,5-inositol triphosphate and DAG,
which can stimulate Ca2+-independent isoforms of
PKC, such as PKC-
and PKC-
.50 The role of DAG in the
activation of PKC is supported by our previous studies14
in which hearts were treated with SAG, a precursor of DAG, and
by our current study with diazoxide. However, translocation of PKC to
sarcolemma or mitochondrial sites was inhibited in hearts after
treatment with 5-HD or chelerythrine. Thus it is reasonable to suggest
that diazoxide, in addition to its effect on the
MitoKATP channel, activates PKC through
the Ca2+-mediated pathway. The significance of
PKC is further indicated by the translocation of its isoform
to the
intercalated disks in diazoxide-treated hearts. It is known that
weakening of intracellular junctions occurs at intercalated disks
during Ca2+ depletion.51 The
translocation of PKC-
to the intercalated disks in diazoxide-treated
hearts may suggest that PKC-
might modulate myocardial function
through cell-to-cell interaction. In light of these findings, the
presence of PKC-
in the cell junctions may contribute to effective
communication and ion exchange that reduces Ca2+
PD injury.
In summary, we conclude that (1) the opening of the MitoKATP channel by diazoxide is mediated by the PKC signaling pathway; (2) the MitoKATP channel is a key player in Ca2+ preconditioning; and (3) a transient increase in Ca2+ effected by CPC or indirectly by diazoxide is a possible trigger for the activation of PKC.
| Acknowledgments |
|---|
Received October 14, 1998; accepted March 4, 1999.
| References |
|---|
|
|
|---|
2.
Ashraf M, Suleiman J, Ahmad M.
Ca2+ preconditioning elicits a unique protection
against the Ca2+ paradox injury in rat heart:
role of adenosine: fixed. Circ Res. 1994;74:360367.
3. Zimmerman ANE, Hulsmann WC. Paradoxical influence of calcium ions on the permeability of the cell membranes of the isolated rat heart. Nature. 1966;211:646647.[Medline] [Order article via Infotrieve]
4. Ganote CE. Contraction band necrosis and irreversible myocardial. J Mol Cell Cardiol. 1983;15:6773.[Medline] [Order article via Infotrieve]
5. Altschuld RA, Ganote CE, Nayler WG, Piper HM. What constitutes the calcium paradox? J Mol Cell Cardiol. 1991;23:765767.[Medline] [Order article via Infotrieve]
6. Ruigrok TJG. Is an increase of intracellular Na+ during Ca2+ depletion essential for the occurrence of the calcium paradox? J Mol Cell Cardiol. 1990;22:499501.[Medline] [Order article via Infotrieve]
7.
Miyawaki H, Ashraf M. Ca2+ as a
mediator of ischemic preconditioning. Circ Res. 1997;80:790799.
8.
Garlid KD, Paucek P, Yarov-Yarovoy V, Murray HN,
Darbenzio RB, D'Alonzo AJ, Lodge NJ, Smith MA, Grover GJ.
Cardioprotective effect of diazoxide and its interaction with
mitochondrial ATP-sensitive K+ channels: possible
mechanism of cardioprotection. Circ Res. 1997;81:10721082.
9.
Liu Y, Sato T, O'Rourke B, Marban E. Mitochondrial
ATP-dependent potassium channels: novel effectors of cardioprotection?
Circulation. 1998;97:24632469.
10.
Garlid KD, Paucek P, Yarov-Yarovoy V, Sun X, Schindler
PA. The mitochondrial KATP channel as a receptor
for potassium channel openers. J Biol Chem. 1996;271:87968799.
11.
Sato T, O'Rourke B, Marban E. Modulation of
mitochondrial ATP-dependent K+ channels by
protein kinase C. Circ Res. 1998;83:110114.
12.
Miyawaki H, Zhou X, Ashraf M. Calcium preconditioning
elicits strong protection against ischemic injury via protein
kinase C signaling pathway. Circ Res. 1996;79:137146.
13.
Miller RJ. Multiple calcium channels and neuronal
function. Science. 1987;235:4652
14.
Wang YG, Ashraf M. Activation of
1-adrenergic receptor during
Ca2+ pre-conditioning elicits strong protection
against Ca2+ overload injury via protein kinase C
signaling pathway. J Mol Cell Cardiol. 1998;30:24232435.[Medline]
[Order article via Infotrieve]
15.
Miyawaki H, Ashraf M. Isoproterenol mimics
calcium preconditioning-induced protection against ischemia.
Am J Physiol. 1997;272:H927H936.
16. Gross GJ, Yao Z, Auchampach JA. Role of ATP-sensitive potassium channels in ischemic preconditioning. In: Przyklenk K, Kloner RA, eds. Ischemic Preconditioning: Concept of Endogenous Cardioprotection. Vol 148. Boston, Mass: Kluwer Academic Publishers. 1994:125135.
17. Paucek P, Yarov-Yarovoy V, Sun X, Garlid KD. Physiological and pharmacological activators of the mitochondrial KATP channel. Biophys J. 1995;68:A145. Abstract.
18. Inoue I, Nagase H, Kishi K, Higuti T. ATP-sensitive K+ channel in the mitochondrial inner membrane. Nature. 1991;352:244247.[Medline] [Order article via Infotrieve]
19. Manon S, Guerin M. Evidence for three different electrophoretic pathways in yeast mitochondria: ion specificity and inhibitor sensitivity. J Bioenerg Biomembr. 1993;25:671678.[Medline] [Order article via Infotrieve]
20. Szewczyk A. The ATP-regulated K+ channel in mitochondria: five years after its discovery. Acta Biochim Pol. 1996;43:713720.[Medline] [Order article via Infotrieve]
21. Cross HR, Radda GK, Clarke K. The role of Na+/K+ ATPase activity during low flow ischemia in preventing myocardial injury: a 31P, 23Na and 87Rb NMR spectroscopic study. Magn Reson Med. 1995;34:673685.[Medline] [Order article via Infotrieve]
22. Opie LH. Role of calcium and other ions in reperfusion injury. Cardiovasc Drugs Ther. 1991;5:237248.
23.
Xu KY, Zweier JL, Becker LC. Functional coupling
between glycolysis and sarcoplasmic reticulum
Ca2+ transport. Circ Res. 1995;77:8897.
24. Halestrap AP. The regulation of the matrix volume of mammalian mitochondria in vivo and in vitro and its role in the control of mitochondrial metabolism. Biochim Biophys Acta. 1989;973:355382.[Medline] [Order article via Infotrieve]
25.
Janczcwski AM, Sollot SJ, Spurgeon HA, Lakatta EG.
Mitochondrial free Ca2+ in single
ventricular myocytes rapidly responds to changes in
cytosolic Ca2+. Circulation. 1992;86:135.
26.
Wendt-Gallitelli MF, Isenberg G. Total and free
myoplasmic calcium during a concentration cycle: X-ray
microanalysis in guinea-pig ventricular myocytes.
J Physiol (Lond). 1991;435:349372.
27.
Gunter TE, Pfeiffer DR. Mechanisms by which
mitochondria transport calcium. Am J Physiol. 1990;258:C755C786.
28. Hunter DR, Haworth RA. Allosteric inhibition of Ca2+ activated hydrophilic channel of the mitochondrial inner membrane by nucleotides. J Membr Biol. 1980;54:231236.[Medline] [Order article via Infotrieve]
29. Hansford RG. Dehydrogenase activation by Ca2+ in cells and tissues. J Bioenerg Biomembr. 1991;23:823854.[Medline] [Order article via Infotrieve]
30. Ferrari R. The role of mitochondria in ischemic heart disease. J Cardiovasc Pharmacol. 1996;28(suppl 1):S1S10.
31.
Quast U, Cook NS. In vitro and in vivo comparison of
two K+ channel openers, diazoxide and cromakalim,
and their inhibition by glibenclamide. J Pharmacol Exp
Ther. 1989;250:261270.
32. Faivre JF, Findlay I. Effects of tolbutamide, glibenclamide and diazoxide upon action potentials recorded from rat ventricular muscle. Biochim Biophys Acta. 1989;984:15.[Medline] [Order article via Infotrieve]
33.
Nishizuka Y. Studies and perspectives of protein kinase
C. Science. 1986;233:305312.
34.
Fiedida D, Braun AP, Giles WR.
1-Adrenoceptors in myocardium:
functional aspects and transmembrane signaling mechanisms.
Pharmacol Rev. 1993;73:469487.
35.
Mitchell MB, Meng X, Ao LH, Brown JM, Harken AH,
Banerjee A. Preconditioning of isolated rat heart is mediated by
protein kinase C. Circ Res. 1995;76:7381.
36. Cohen MV, Downey JM. Myocardial preconditioning promises to be a novel approach to the treatment of ischemic heart disease. Annu Rev Med. 1996;47:2129.[Medline] [Order article via Infotrieve]
37. Schultz G, Senft G, W Losert, Sitt R. Biochemische grundlagen der diazoxide-hyperglykamie. Arch Exp Pathol Pharmakol. 1966;253:372387.
38. Moore PF. The effects of diazoxide and benzothiadiazine diuretics upon phosphodiesterase. Ann N Y Acad Sci. 1968;150:256260.[Medline] [Order article via Infotrieve]
39. Pagani ED, Buchholz RA, Silver PJ. Cardiovascular cyclic nucleotide phosphodiesterases and their role in regulating cardiovascular function. Basic Res Cardiol. 1992;87:7386.
40. Tsien RW, Bean BP, Hess P, Lansman JB, Nilius B, Nowycky MC. Mechanisms of calcium channel modulation by ßadrenergic agents and dihydropyridine calcium agonists. J Mol Cell Cardiol. 1986;18:691710.[Medline] [Order article via Infotrieve]
41.
Miyawaki H, Wang YG, Ashraf M. Oxidant stress
with hydrogen peroxide attenuates calcium paradox injury: role of
protein kinase C and ATP-sensitive potassium channel. Cardiovasc
Res. 1998;37:691699.
42.
Przyklenk K, Hata K, Kloner RA. Is calcium a mediator
of infarct size reduction with preconditioning in canine myocardium?
Circulation.. 1997;96:13051312.
43.
Meldrum DR, Cleveland JC, Mitchell MB, Sheridan BC,
Gamboni-Robertson F, Harken AH, Banerjee A. Protein kinase C mediates
Ca2+-induced cardioprotection to ischemia-reperfusion
injury. Am J Physiol.. 1996;271:R718R729.
44.
DeWeille JR, Schmid-Antomarchi H, Fosset M, Lazdunski
M. Regulation of ATP-sensitive K+ channels in
insulinoma cells: activation by somatostation and protein kinase C and
the role of cAMP. Proc Natl Acad Sci U S A. 1989;86:29712975.
45. Houslay MD. `Crosstalk': a pivotal role for protein kinase C in modulating relationships between signal transduction pathway. Eur J Biochem. 1991;195:927. Review.[Medline] [Order article via Infotrieve]
46. Moraru II, Jones RM, Popescu LM, Engelman RM, Das DK. Prazosin reduces myocardial ischemia/reperfusion-induced Ca2+ overloading in rat heart by inhibiting phosphoinositide signaling. Biochim Biophys Acta. 1995;1268:18.[Medline] [Order article via Infotrieve]
47.
Henrich CJ, Simpson PC. Differential acute and
chronic response of protein kinase C in cultured neonatal rat heart
myocytes to
1-adrenergic and phorbol
ester stimulation. J Mol Cell Cardiol. 1988;20:10811085.[Medline]
[Order article via Infotrieve]
48. Disatnik MH, Buraggi G, Mochly-Rosen D. Localization of protein kinase C isozymes in cardiac myocytes. Exp Cell Res. 1994;210:287297.[Medline] [Order article via Infotrieve]
49. Holmuhamedov EL, Jovanovic S, Dzeja PP, Jovanovic A, Terzic A. Mitochondrial ATP-sensitive K+ channels modulate cardiac mitochondrial function. Am J Physiol. 1998;275(pt 2):H1567H1576.
50.
Nishizuka Y. Intracellular signaling by hydrolysis of
phospholipids and activation of protein kinase C. Science. 1992;258:607614.
51. Ashraf M. Correlative studies on sarcolemmal ultrastructure, permeability, and loss of intracellular enzymes in the isolated heart perfused with calcium-free medium. Am J Pathol. 1979;97:411432.[Abstract]
This article has been cited by other articles:
![]() |
S. J. Clarke, I. Khaliulin, M. Das, J. E. Parker, K. J. Heesom, and A. P. Halestrap Inhibition of Mitochondrial Permeability Transition Pore Opening by Ischemic Preconditioning Is Probably Mediated by Reduction of Oxidative Stress Rather Than Mitochondrial Protein Phosphorylation Circ. Res., May 9, 2008; 102(9): 1082 - 1090. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Bouwman, R. J. P. Musters, B. J. van Beek-Harmsen, J. J. de Lange, R. R. Lamberts, S. A. Loer, and C. Boer Sevoflurane-induced cardioprotection depends on PKC-{alpha} activation via production of reactive oxygen species Br. J. Anaesth., November 1, 2007; 99(5): 639 - 645. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Garg and K. Hu Protein kinase C isoform-dependent modulation of ATP-sensitive K+ channels in mitochondrial inner membrane Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H322 - H332. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wang, N. Ahmad, B. Wang, and M. Ashraf Chronic preconditioning: a novel approach for cardiac protection Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2300 - H2305. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-S. Park, E.-M. Hur, B.-H. Choi, E. Kwak, D.-J. Jun, S.-J. Park, and K.-T. Kim Involvement of Protein Kinase C-{varepsilon} in Activity-Dependent Potentiation of Large Dense-Core Vesicle Exocytosis in Chromaffin Cells. J. Neurosci., August 30, 2006; 26(35): 8999 - 9005. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. J. Grover Mitochondrial ATP-sensitive potassium channels and mitochondrial protein kinase C: sometimes it's good to have a close neighbor Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H1752 - H1753. [Full Text] [PDF] |
||||
![]() |
M. T. Jiang, M. Ljubkovic, Y. Nakae, Y. Shi, W.-M. Kwok, D. F. Stowe, and Z. J. Bosnjak Characterization of human cardiac mitochondrial ATP-sensitive potassium channel and its regulation by phorbol ester in vitro Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H1770 - H1776. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Inagaki, E. Churchill, and D. Mochly-Rosen Epsilon protein kinase C as a potential therapeutic target for the ischemic heart Cardiovasc Res, May 1, 2006; 70(2): 222 - 230. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Hausenloy and D. M. Yellon Survival kinases in ischemic preconditioning and postconditioning Cardiovasc Res, May 1, 2006; 70(2): 240 - 253. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D.T. Costa, K. D. Garlid, I. C. West, T. M. Lincoln, J. M. Downey, M. V. Cohen, and S. D. Critz Protein Kinase G Transmits the Cardioprotective Signal From Cytosol to Mitochondria Circ. Res., August 19, 2005; 97(4): 329 - 336. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Wang, L. Jia, T. Wang, W. Sun, S. Wu, and X. Wang Endogenous Calcitonin Gene-related Peptide Protects Human Alveolar Epithelial Cells through Protein Kinase C{epsilon} and Heat Shock Protein J. Biol. Chem., May 27, 2005; 280(21): 20325 - 20330. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wang, N. Ahmad, M. Kudo, and M. Ashraf Contribution of Akt and endothelial nitric oxide synthase to diazoxide-induced late preconditioning Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1125 - H1131. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Mayr, B. Metzler, Y.-L. Chung, E. McGregor, U. Mayr, H. Troy, Y. Hu, M. Leitges, O. Pachinger, J. R. Griffiths, et al. Ischemic preconditioning exaggerates cardiac damage in PKC-{delta} null mice Am J Physiol Heart Circ Physiol, August 1, 2004; 287(2): H946 - H956. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Zaugg, M. C. Schaub, and P. Foex Myocardial injury and its prevention in the perioperative setting Br. J. Anaesth., July 1, 2004; 93(1): 21 - 33. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Loubani, A. Hassouna, and M. Galinanes Delayed preconditioning of the human myocardium: signal transduction and clinical implications Cardiovasc Res, February 15, 2004; 61(3): 600 - 609. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Gamboa, A. C. Ertl, F. Costa, G. Farley, M. L. Manier, D. L. Hachey, A. Diedrich, and I. Biaggioni Blockade of Nucleoside Transport Is Required for Delivery of Intraarterial Adenosine Into the Interstitium: Relevance to Therapeutic Preconditioning in Humans Circulation, November 25, 2003; 108(21): 2631 - 2635. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. de Ruijter, R. J.P. Musters, C. Boer, G. J. M. Stienen, W. S. Simonides, and J. J. de Lange The Cardioprotective Effect of Sevoflurane Depends on Protein Kinase C Activation, Opening of Mitochondrial K+ATP Channels, and the Production of Reactive Oxygen Species Anesth. Analg., November 1, 2003; 97(5): 1370 - 1376. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Leducq, F. Bono, T. Sulpice, V. e. Vin, P. Janiak, G. L. Fur, S. E. O'Connor, and J.-M. Herbert Role of Peripheral Benzodiazepine Receptors in Mitochondrial, Cellular, and Cardiac Damage Induced by Oxidative Stress and Ischemia-Reperfusion J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 828 - 837. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. J. Gross and J. N. Peart KATP channels and myocardial preconditioning: an update Am J Physiol Heart Circ Physiol, August 7, 2003; 285(3): H921 - H930. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. C. Zhao and R. C. Kukreja Protein kinase C-{delta} mediates adenosine A3 receptor-induced delayed cardioprotection in mouse Am J Physiol Heart Circ Physiol, June 5, 2003; 285(1): H434 - H441. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. N. Peart and G. J. Gross Adenosine and opioid receptor-mediated cardioprotection in the rat: evidence for cross-talk between receptors Am J Physiol Heart Circ Physiol, June 5, 2003; 285(1): H81 - H89. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ichinose, H. Yonemochi, T. Sato, and T. Saikawa Diazoxide triggers cardioprotection against apoptosis induced by oxidative stress Am J Physiol Heart Circ Physiol, June 1, 2003; 284(6): H2235 - H2241. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Das, J. E Parker, and A. P Halestrap Matrix volume measurements challenge the existence of diazoxide/glibencamide-sensitive KATP channels in rat mitochondria J. Physiol., March 15, 2003; 547(3): 893 - 902. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Peart, L. Willems, and J. P. Headrick Receptor and non-receptor-dependent mechanisms of cardioprotection with adenosine Am J Physiol Heart Circ Physiol, February 1, 2003; 284(2): H519 - H527. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M Bell, H. L Maddock, and D. M Yellon The cardioprotective and mitochondrial depolarising properties of exogenous nitric oxide in mouse heart Cardiovasc Res, February 1, 2003; 57(2): 405 - 415. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. P. Raval, K. R. Dave, D. Mochly-Rosen, T. J. Sick, and M. A. Perez-Pinzon epsilon PKC Is Required for the Induction of Tolerance by Ischemic and NMDA-Mediated Preconditioning in the Organotypic Hippocampal Slice J. Neurosci., January 15, 2003; 23(2): 384 - 391. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-P. Wang, H. Maeta, K. Mizoguchi, T. Suzuki, Y. Yamashita, and M. Oe Intestinal ischemia preconditions myocardium: role of protein kinase C and mitochondrial KATP channel Cardiovasc Res, August 15, 2002; 55(3): 576 - 582. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kudo, Y. Wang, M. Xu, A. Ayub, and M. Ashraf Adenosine A1 receptor mediates late preconditioning via activation of PKC-delta signaling pathway Am J Physiol Heart Circ Physiol, July 1, 2002; 283(1): H296 - H301. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Ohnuma, T. Miura, T. Miki, M. Tanno, A. Kuno, A. Tsuchida, and K. Shimamoto Opening of mitochondrial KATP channel occurs downstream of PKC-epsilon activation in the mechanism of preconditioning Am J Physiol Heart Circ Physiol, July 1, 2002; 283(1): H440 - H447. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. P. Baines, J. Zhang, G.-W. Wang, Y.-T. Zheng, J. X. Xiu, E. M. Cardwell, R. Bolli, and P. Ping Mitochondrial PKC{epsilon} and MAPK Form Signaling Modules in the Murine Heart: Enhanced Mitochondrial PKC{epsilon}-MAPK Interactions and Differential MAPK Activation in PKC{epsilon}-Induced Cardioprotection Circ. Res., March 8, 2002; 90(4): 390 - 397. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Szewczyk and L. Wojtczak Mitochondria as a Pharmacological Target Pharmacol. Rev., March 1, 2002; 54(1): 101 - 127. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. P. Goldberg, S. B. Digerness, J. L. Skinner, C. R. Killingsworth, C. R. Katholi, and W. L. Holman Ischemic preconditioning and Na+/H+ exchange inhibition improve reperfusion ion homeostasis Ann. Thorac. Surg., February 1, 2002; 73(2): 569 - 574. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Fryer, Y. Wang, A. K. Hsu, H. Nagase, and G. J. Gross Dependence of delta 1-Opioid Receptor-Induced Cardioprotection on a Tyrosine Kinase-Dependent but Not a Src-Dependent Pathway J. Pharmacol. Exp. Ther., November 1, 2001; 299(2): 477 - 482. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Mubagwa and W. Flameng Adenosine, adenosine receptors and myocardial protection: An updated overview Cardiovasc Res, October 1, 2001; 52(1): 25 - 39. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wang, E. Takashi, M. Xu, A. Ayub, and M. Ashraf Downregulation of Protein Kinase C Inhibits Activation of Mitochondrial KATP Channels by Diazoxide Circulation, July 3, 2001; 104(1): 85 - 90. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Haller, S. L. Mironov, and D. W. Richter Intrinsic Optical Signals in Respiratory Brain Stem Regions of Mice: Neurotransmitters, Neuromodulators, and Metabolic Stress J Neurophysiol, July 1, 2001; 86(1): 412 - 421. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Stamm, I. Friehs, D. B. Cowan, H. Cao-Danh, S. Noria, M. Munakata, F. X. McGowan Jr., and P. J. del Nido Post-ischemic PKC inhibition impairs myocardial calcium handling and increases contractile protein calcium sensitivity Cardiovasc Res, July 1, 2001; 51(1): 108 - 121. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Liu and B. O'Rourke Opening of Mitochondrial KATP Channels Triggers Cardioprotection : Are Reactive Oxygen Species Involved? Circ. Res., April 27, 2001; 88(8): 750 - 752. [Full Text] [PDF] |
||||
![]() |
R. M. Fryer, Y. Wang, A. K. Hsu, and G. J. Gross Essential activation of PKC-{delta} in opioid-initiated cardioprotection Am J Physiol Heart Circ Physiol, March 1, 2001; 280(3): H1346 - H1353. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Xu, Y. Wang, K. Hirai, A. Ayub, and M. Ashraf Calcium preconditioning inhibits mitochondrial permeability transition and apoptosis Am J Physiol Heart Circ Physiol, February 1, 2001; 280(2): H899 - H908. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Wang, J. Cone, and Y. Liu Dual roles of mitochondrial KATP channels in diazoxide-mediated protection in isolated rabbit hearts Am J Physiol Heart Circ Physiol, January 1, 2001; 280(1): H246 - H255. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Huh, G. J. Gross, H. Nagase, and B. T. Liang Protection of cardiac myocytes via {delta}1-opioid receptors, protein kinase C, and mitochondrial KATP channels Am J Physiol Heart Circ Physiol, January 1, 2001; 280(1): H377 - H383. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. O'Rourke Pathophysiological and protective roles of mitochondrial ion channels J. Physiol., November 15, 2000; 529(1): 23 - 36. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. O'Rourke Myocardial KATP Channels in Preconditioning Circ. Res., November 10, 2000; 87(10): 845 - 855. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Weekers, E. Van Herck, J. Isgaard, and G. Van den Berghe Pretreatment with Growth Hormone-Releasing Peptide-2 Directly Protects against the Diastolic Dysfunction of Myocardial Stunning in an Isolated, Blood-Perfused Rabbit Heart Model Endocrinology, November 1, 2000; 141(11): 3993 - 3999. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. J. Gross and R. M. Fryer Mitochondrial KATP Channels : Triggers or Distal Effectors of Ischemic or Pharmacological Preconditioning? Circ. Res., September 15, 2000; 87(6): 431 - 433. [Full Text] [PDF] |
||||
![]() |
T. Pain, X.-M. Yang, S. D. Critz, Y. Yue, A. Nakano, G. S. Liu, G. Heusch, M. V. Cohen, and J. M. Downey Opening of Mitochondrial KATP Channels Triggers the Preconditioned State by Generating Free Radicals Circ. Res., September 15, 2000; 87(6): 460 - 466. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J. Tanhehco, K. Yasojima, P. L. McGeer, E. G. McGeer, and B. R. Lucchesi Preconditioning reduces myocardial complement gene expression in vivo Am J Physiol Heart Circ Physiol, September 1, 2000; 279(3): H1157 - H1165. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Miura, Y. Liu, H. Kita, T. Ogawa, and K. Shimamoto Roles of mitochondrial ATP-sensitive K channels and PKC in anti-infarct tolerance afforded by adenosine A1 receptor activation J. Am. Coll. Cardiol., January 1, 2000; 35(1): 238 - 245. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Sato Signaling in Late Preconditioning : Involvement of Mitochondrial KATP Channels Circ. Res., December 3, 1999; 85(12): 1113 - 1114. [Full Text] [PDF] |
||||
![]() |
E. Takashi, Y. Wang, and M. Ashraf Activation of Mitochondrial KATP Channel Elicits Late Preconditioning Against Myocardial Infarction via Protein Kinase C Signaling Pathway Circ. Res., December 3, 1999; 85(12): 1146 - 1153. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Ockaili, V. R. Emani, S. Okubo, M. Brown, K. Krottapalli, and R. C. Kukreja Opening of mitochondrial KATP channel induces early and delayed cardioprotective effect: role of nitric oxide Am J Physiol Heart Circ Physiol, December 1, 1999; 277(6): H2425 - H2434. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wang, K. Hirai, and M. Ashraf Activation of Mitochondrial ATP-Sensitive K+ Channel for Cardiac Protection Against Ischemic Injury Is Dependent on Protein Kinase C Activity Circ. Res., October 15, 1999; 85(8): 731 - 741. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ishida, Y. Hirota, C. Genka, H. Nakazawa, H. Nakaya, and T. Sato Opening of Mitochondrial KATP Channels Attenuates the Ouabain-Induced Calcium Overload in Mitochondria Circ. Res., November 9, 2001; 89(10): 856 - 858. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |